4881.T
The company operates in the healthcare diagnostics sector, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. The company operates in the healthcare diagnostics sector, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics sector, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
The company maintains a strong liquidity position, with a current ratio of 3.74, indicating that it has sufficient current assets to cover its current liabilities. The company's price-to-book ratio is 1.88, suggesting that the market value is trading at a premium to its book value. The company's price-to-tangible-book ratio is also 1.88, which is consistent with the price-to-book ratio, indicating that the company's intangible assets do not significantly affect the valuation.
The company's profitability is currently negative, with a return on equity of -1.3056 and a return on assets of -0.965, indicating that it is not generating returns for its shareholders or assets. The company's operating income is -2026288000.0, and its net income is -1911528000.0, reflecting a significant loss in operations. The company's gross profit is equal to its revenue, suggesting that it is not incurring any cost of goods sold, which is unusual and may indicate a reporting anomaly or a specific business model.
The company's revenue is concentrated in a single segment, as there are no disclosed segments, and it operates primarily in Japan, as indicated by the JPY financial reporting. The company's revenue is 314000.0, and there is no information on geographic distribution or segment performance.
The company's growth trajectory is uncertain, as there is no outlook data provided for the current or next fiscal year. The company's operating cash flow is -1387571000.0, and its free cash flow is -1869987000.0, indicating that it is not generating positive cash flows from operations. The company's capital expenditure is -348000.0, which is a small outlay relative to its cash and equivalents of 1768476000.0.
The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.0, indicating that it is not leveraged and does not have long-term debt. The company's dilution potential is low, with no dilution sources identified in the available data.
There are no recent events or filings mentioned in the provided data that would impact the company's operations or financial position. The company's market price is 60.0, and its market cap is 2756975280.0, with a mean price target of 320.00 JPY from analysts. The company's analyst recommendations are mixed, with one buy recommendation and no strong buy or hold recommendations.
- The company has a strong liquidity position with a current ratio of 3.74.
- The company is not generating returns for its shareholders or assets, with a negative return on equity and return on assets.
- The company's revenue is concentrated in a single segment and operates primarily in Japan.
- The company's growth trajectory is uncertain, with no outlook data provided for the current or next fiscal year.
- The company has low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected.
- margin_outlook_rationale: The company's margin outlook is uncertain due to the lack of provided outlook data for the current or next fiscal year.
- rd_outlook_rationale: The company's research and development outlook is not specified in the available data.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -19,90 |
| Revenue | —no estimate | —no estimate | 300,0M JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 4881.T Market data — financials · 2026-05-26
- FunPep Co Ltd Market data — analyst estimates · 2026-05-26